Bone marrow aspirate concentrate (BMAC)

Bone marrow aspirate concentrate (BMAC) is a complex, autologous biological mixture obtained by centrifuging bone marrow aspirate to concentrate regenerative cells and signaling molecules. It contains a diverse population of cells, including mesenchymal stem cells (MSCs), hematopoietic stem cells (HSCs), and various progenitor cells, alongside a high concentration of growth factors such as platelet-derived growth factor (PDGF) and transforming growth factor-beta (TGF-beta). BMAC is widely employed in orthopedic and regenerative medicine to treat conditions like osteoarthritis, bone non-unions, and tendon injuries by promoting tissue healing and reducing inflammation (NIH, 2022; PubMed: 31501209). The therapeutic mechanism involves both the direct action of progenitor cells and the paracrine effects of secreted cytokines that stimulate angiogenesis and modulate the immune response. As a point-of-care autologous therapy, it avoids the risks of graft-versus-host disease but suffers from significant inter-patient variability in cellular composition and potency.

Other names

Bone marrow concentrateBMCAutologous bone marrow aspirate concentrateBMAC therapyBone marrow cell concentrate

Bone marrow aspirate concentrate (BMAC) functions through the delivery of a concentrated population of regenerative cells and bioactive factors. Mesenchymal stem cells (MSCs) within the concentrate can differentiate into various musculoskeletal lineages and secrete paracrine factors that modulate the local inflammatory environment. These cells, along with hematopoietic stem cells and endothelial progenitors, release growth factors such as vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF), and transforming growth factor-beta (TGF-beta), which collectively stimulate angiogenesis, recruit endogenous repair cells, and promote extracellular matrix synthesis (StatPearls, 2023; PubMed: 27048223).